Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis.
Manon LaunayLaure RaymondJérôme GuittonMarie-Anne LoriotEtienne ChatelutVincent HaufroidFabienne ThomasMarie-Christine Etienne-GrimaldiPublished in: Clinical chemistry and laboratory medicine (2024)
genotyping is not sufficiently reliable to identify all patients with complete deficiency.